Compare LyondellBasell Industries NV (LYB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs TG Therapeutics Inc — how do they compare? LyondellBasell Industries NV trades at $60.13 (market cap $19.49B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: LyondellBasell Industries NV is far larger — about 2.4× TG Therapeutics Inc's market cap, and LyondellBasell Industries NV pays a 4.57% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LyondellBasell Industries NV for 87 Days and TG Therapeutics Inc for 16 Days on average.
| LYB | TGTX | |
|---|---|---|
Market Cap | $19.49B | $8.16B |
Volume | 6,033,396 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $59.06 |
52-Week Low | $42.28 | $26.94 |
Typical Hold Time | 87 Days | 16 Days |
Enterprise Value | $31.08B | $8.37B |
Dividend Yield | 4.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $60.03, up 2.63% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $4.30 beating expectations of $3.44, but faces fundamental challenges with negative net income margin of -1.13% and declining revenue from $50.5B in 2022 to $30.2B in 2025. Analyst consensus remains divided with 45% buy and 45% hold ratings, targeting $69.38 average price.
LYB shows operational resilience with improving cash flow projections for 2026, but faces significant headwinds from declining profitability and competitive pressures. The dividend yield remains attractive but sustainability concerns persist given the negative earnings trend. Near-term upside exists if operational improvements continue, though investors should monitor debt levels and chemical sector cyclicality.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
